Next Article in Journal
Three Method-Combination Protocol for Improving Purity of Extracellular Vesicles
Next Article in Special Issue
NF-κB and Its Role in Checkpoint Control
Previous Article in Journal
Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis
Previous Article in Special Issue
HIF-1β Positively Regulates NF-κB Activity via Direct Control of TRAF6
Open AccessReview

Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View

Department of Biological, Chemical and Pharmaceutical Science and Technology (STEBICEF), University of Palermo, 90128 Palermo, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(9), 3070; https://doi.org/10.3390/ijms21093070
Received: 8 April 2020 / Revised: 24 April 2020 / Accepted: 25 April 2020 / Published: 27 April 2020
(This article belongs to the Special Issue NF-κB and Disease)
Multidrug resistance (MDR), of the innate and acquired types, is one of major problems in treating tumor diseases with a good chance of success. In this review, we examine the key role of nuclear factor-kappa B (NF-κB) to induce MDR in three tumor models characterized precisely by innate or acquired MDR, in particular triple negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and acute myeloid leukemia (AML). We also present different pharmacological approaches that our group have employed to reduce the expression/activation of this transcriptional factor and thus to restore chemo-sensitivity. Finally, we examine the latest scientific evidence found by other groups, the most significant clinical trials regarding NF-κB, and new perspectives on the possibility to consider this transcriptional factor a valid drug target in neoplastic diseases. View Full-Text
Keywords: MDR; cancer; NF-κB; drug target MDR; cancer; NF-κB; drug target
Show Figures

Graphical abstract

MDPI and ACS Style

Labbozzetta, M.; Notarbartolo, M.; Poma, P. Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View. Int. J. Mol. Sci. 2020, 21, 3070.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop